曲安奈德后部眼球筋膜下注射与雷珠单抗玻璃体内注射治疗缺血性视神经病变的疗效对比

Comparison of efficacy between subtenon injection of triamcinolone acetonide and intravitreal injection of ranibizumab for non-arteritic anterior ischenic optic neuropathy

目的比较曲安奈德后部眼球筋膜下注射雷珠单抗玻璃体内注射治疗非动脉炎性前部缺血性视神经病变(NAION)的效果。方法回顾性分析2016年6月至2018年6月临床确诊的NAION 60例(60眼)随机分为两组。A组30例(30眼)曲安奈德20 mg后部眼球筋膜下注射;B组30例(30眼)雷珠单抗玻璃体内注射;均为15天为1个疗程。观察治疗后视力、视盘水肿情况及视野。结果治疗后15天,两组视力、视野及视盘水肿情况均有不同程度改善,后部眼球筋膜下注射组有视野检查15眼中治疗后好转14眼(93.33%),1眼无变化(6.67%)。雷珠单抗玻璃体内注射组有视野检查记录的15眼中治疗后视野好转12眼(83.33%),3眼无变化(16.67%)。结论曲安奈德与雷珠单抗治疗NAION有同等的疗效。曲安奈德在经济学方面及安全方面优于雷珠单抗组。

Objective To compare the efficary between posterior subtenon injection of triamcinolone acetonide(TA)and intravitreal injection of ranibizumab for the treatment of non-artertic anterior ischemic optic neuropathy (NAION). Methods Total of 60 eyes of 60 patients who were diagnosed as NAION from Jun. 2016 to Jun. 2018 were randomly divided into two groups.Group A, 30 eyes of 30 patients, received poeterior subtenon injection of triamcinolone acetonide (TA, 20mg). Group B, 30 eyes of 30 cases, received intravitreal injection of ranibizumab. The visual acuity, visual field and optic disc edema were recorded after treatment. Results The visual acuity, visual field and optic disc edema at 15 days after treatment were improved.In group A the vision field improved in 14 eyes (93.33%)among 15 eyes who received visual field examination, unchannged in 1 eye (6.67%). In group B the vision field were improved in 12 eyes(83.33%)among 15 eyes who received visual field examination, and unchannged in 3 eyes(16.67%). Conclusion Triamcinolone acetonide (TA) has the same efficacy as ranibizumab in the treatment of NAION.Triamcinolone acetonide are superior to Ranibizumab in economics and safety.